Avidity Partners Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Avidity Partners Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-97,000	Closed	-$8.1M	–	85
2024 Q4	$8.1M	Sell	97,000 -136,000	-58%	-$11.2M	0.8%	45
2024 Q3	$17M	Sell	233,000 -167,000	-42%	-$12.6M	0.87%	46
2024 Q2	$27.4M	Sell	400,000 -200,000	-33%	-$13.9M	1.16%	35
2024 Q1	$41.5M	Sell	600,000 -110,000	-15%	-$7.56M	1.34%	27
2023 Q4	$50.9M	Sell	710,000 -91,100	-11%	-$5.24M	1.85%	21
2023 Q3	$41.7M	Buy	+801,100	New	+$46.7M	1.68%	22
2023 Q1	–	Sell	-504,000	Closed	-$26.7M	–	98
2022 Q4	$26.7M	Sell	504,000 -898,500	-64%	-$45M	0.58%	45
2022 Q3	$65.3M	Buy	1,402,500 +626,996	+81%	+$32.8M	1.33%	27
2022 Q2	$44.3M	Buy	+775,504	New	+$44M	1.02%	30

Other funds holding ITCI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Avidity Partners Management's ITCI Position: Q1 2025 in Review

Avidity Partners Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 97,000 shares — an estimated $8.1M sold.

Avidity Partners Management first reported a position in ITCI in Q2 2022 and held it in 9 quarters. The position peaked at $65.3M in Q3 2022. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

Avidity Partners Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
Avidity Partners Management sold 97,000 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $8.1M.
Avidity Partners Management first reported a position in Intra-Cellular Therapies Inc. in Q2 2022 and held it in 9 quarters.
Avidity Partners Management's Intra-Cellular Therapies Inc. position peaked at $65.3M in Q3 2022.
395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Avidity Partners Management's 13F filing for Q1 2025, filed 15 May 2025.